血尿酸及血脂水平与帕金森病发病的相关性分析

doi:10.3969/j.issn.1671-7171.2022.08.007

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1151 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the relationship between serum uric acid (UA), triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and the onset of Parkinson's disease (PD). 【Methods】A total of 136 PD patients (PD group) and 91 healthy persons (control group) treated in our hospital from January 2019 to August 2020 were collected, and the levels of UA, TG, TC, LDL-C and HDL-C were compared between the two groups; According to Hoehn Yahr (H-Y) stage, PD patients were divided into three subgroups:early stage, middle stage and late stage, and the UA levels of different subgroups were compared; The influencing factors of PD incidence were analyzed by binary logistic regression. 【Results】The levels of UA, TG, TC, LDL-C and HDL-C in the PD group were significantly lower than those in the control group (P<0.05). The UA level in the PD group was significantly lower than that in the control group (P<0.05); There was no significant difference in UA level between women in the PD group and those in the control group (P>0.05). The UA level of PD patients in different stages was significantly different (P<0.05). Binary logistic regression analysis showed that UA and HDL-C levels were correlated with the onset of PD, and high blood UA and HDL-C levels were protective factors for the onset of PD. 【Conclusion】 The levels of UA and HDL-C are related to the pathogenesis of PD.

Key words： Parkinson Disease Uric Acid/BL Triglycerides/BL Cholesterol, HDL/BL Cholesterol, LDL/BL

Received: 08 March 2022

PACS:

R322.81

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHONG Yi
	WANG Kai
	SHEN Pei

Cite this article:

ZHONG Yi,WANG Kai,SHEN Pei. Correlation Analysis of Serum Uric Acid and Blood Lipid Levels with Parkinson's Disease[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(8): 1141-1143.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.08.007 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I8/1141

[1] SULZER D,SURMEIER D J. Neuronal vulnerability,pathogenesis,and Parkinson's diseases[J].Mov Disord,2013,28(1):41-50.
[2] BUSE C,ESMA K,FUSUN M,et al. Uric acid:The role in the pathophysiology and the prediction in the diagnosis of Parkinson's disease:A Turkish-based study[J].Ideggyogy Sz,2022,75(1):51-59.
[3] CHRISTOS K.Serum uric acid level as a biomarker in idiopathic and genetic (p.A53T Alpha-Synuclein Carriers) parkinson's disease:data from the PPMI study[J].J Parkinsons Dis,2020,10(2):481-487.
[4] ASCHERIO A,LEWITT P A,XU K,et al. Urate as a predictor of the rate of clinical decline in Parkinson disease[J].Arch Neurol,2009,66(12):1460-1468.
[5] GAO X,O'REILLY E J,SCHWARZSCHILD M A,et al. Prospective study of plasma urate and risk of Parkinson disease in men and women[J].Neurology,2016,86(6):520-526.
[6] FU X,WANG Y,HE X,et al. A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients and with Parkinson's disease[J].Lipids Health Dis,2020,19(1):97.
[7] RIZZO G,COPETTI M,ARCUTI S,et al. Accuracy of clinical diagnosis of Parkinson disease:a systematic review and meta analysis [J].Neurology,2016,86(6):566-576.
[8] 孔雪燕,蒋森,杨新玲. 帕金森病与血尿酸水平的相关性研究[J].新疆医学,2019,49(4):350-353.
[9] SCHWARZSCHILD M A,ASCHERIO A,BEAL M F,et al.Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease:a randomized clinical trial[J].JAMA Neurol,2014,71(2):141-150.
[10] SIMON K C,EBERLY S,GAO X,et al. Mendelian randomization of serum urate and Parkinson disease progression[J].Ann Neurol,2014,76(6):862-868.
[11] SCHWARZSCHILD M A,SCHWID S R,MAREK K,et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease[J].Arch Neurol,2008,65(6):716-723.
[12] ANDREADOU E,NIKOLAOU C,GOURNARAS F,et al. Serum uric acid levels in patients with Parkinson's disease:their relationship to treatment and disease duration[J].Clin Neurol Neurosurg,2009,111(9):724-728.
[13] 徐凡茜,张海南,王春,等.血脂水平与帕金森病相关性的Meta分析[J].中国医师杂志,2019,7(21):1024-1029.
[14] 田荆华,朱明慧,张争辉,等.帕金森病猴模型生化指标及肾上腺的改变[J].中国临床解剖学杂志,2019,37(1):51-54.
[15] 陈慧敏,张美美,王伊龙. 增龄相关脑白质高信号与帕金森病脑萎缩及认知障碍的相关性[J] .中华医学杂志,2020,100 (43):3397-3401.
[16] HU G,ANTIKAINEN R,JOUSILAHTI P,et al. Total cholesterol and the risk of Parkinson disease[J].Neurology,2008,70(21):1972-1979.
[17] 王扬扬,史长河,吴峥嵘,等.帕金森病患者血脂表达情况的研究[J].神经损伤与功能重建,2015,10(3):207-209.
[18] 戚志强,张克忠,王胜龙,等. 帕金森病患者血脂水平的变化及其临床相关性研究[J].中华老年心脑血管病杂志,2016,18(2):119-121.
[19] CASSANI E,CEREDA E,BARICHELLA M,et al. Cardiometabolic factors and disease duration in patients with Parkinson's disease[J].Nutrition,2013,29(11-12):1331-1335.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(8): 1248-1250.